On 27 Oct 2026, ZHAOKE OPHTH-B (06622.HK) said its Guangzhou Nansha site obtained TGA GMP certification, supporting its overseas registration plans.
On October 26, 2026, LEADS BIOLABS-B (09887.HK) reported ESMO 2026 data for LBL-024, with median OS of 8.7 months in third-line or later EP-NEC, a 12-month OS rate of 39.4% and an ORR of 70.0% in first-line BTC.
On October 26, 2026, ALPHAMAB-B (09966.HK) announced that Phase III results of Anbenitamab (KN026) in first-line HER2+ breast cancer and second-line or later HER2+ gastric cancer were presented at the 2026 ESMO Congress as LBA oral presentations.
This week's Going Global Weekly was defined by two main threads, namely out-licensing by pharmaceutical companies and A-share listings in Hong Kong. On the licensing side, HANSOH PHARMA entered into an ADC collaboration with Roche with an upfront payment of USD 400 million and potential milestones exceeding USD 15 billion, METIS TECHBIO-P partnered with Eli Lilly on LNP delivery, HUTCHMED completed the closing of its licence transaction with GSK, and INSILICO triggered a milestone payment from Servier. On the financing side, DSBJ and MICRO-INTELLIGENCE launched their offerings in the same week and are expected to list on October 28. On the M&A side, ORBUSNEICH completed the acquisition of an Italian distributor, RIBOLIFE moved to full ownership of a Swedish R&D centre, and LOPAL TECH sold a 76% stake in its Indonesian subsidiary.
On 22 October 2026, LOPAL TECH (02465.HK) said its unit will sell 76% of PT LBM Energi Baru for USD 31.92 million to make it a non-prohibited foreign entity.
On 21 Oct 2026, SFQ GLOBAL (01953.HK) said its unit signed a US$41.4mn EPC contract for a solar and storage project in the Democratic Republic of the Congo.
On 21 October 2026, ABBISKO-B (02256.HK) said its FGFR2/3 inhibitor lavengratinib (ABSK061) won EMA orphan designation for achondroplasia.
On 21 October 2026, CUTIA-B (02487.HK) expanded its CU-20401 deal with Hangzhou Guansu beyond Asia, letting both parties license it to third parties there.
LEADS BIOLABS-B's LBL-024 received FDA Fast Track Designation, HANSOH PHARMA's EU Marketing Authorisation Application for aumolertinib was accepted by the EMA, and WASION HOLDINGS' AMI meters passed U.S. ANSI certification and secured smart grid orders worth approximately RMB 1.25 billion in the Middle East. On the financing side, TRANSSION listed its H shares at HKD 35.30 per share, SWL TOUR launched its global offering, and TENCENT completed the pricing of USD 1.8 billion and RMB 26 billion of notes.
In 2026, IDC named DEEPZERO (02723.HK) a Leader in its global B2C enterprise agentic marketing assessment, the only Chinese company selected in the evaluation.
In 2026, IDC named DEEPZERO (02723.HK) a Leader in its first global B2C enterprise agentic marketing assessment, the only Chinese company selected.
In September 2026, IDC named DEEPZERO (02723.HK) a Leader in its worldwide B2C enterprise agentic marketing assessment, the only Chinese company listed.
On 13 October 2026, ALCO HOLDINGS (00328.HK) signed long-term deals with distributors in Brazil and Chile to sell its laptops and tablets there.
On 12 October 2026, LEADS BIOLABS-B (09887.HK) said vilasumu, a PD-L1/4-1BB bispecific antibody, received FDA Fast Track designation for first-line advanced biliary tract cancer, granted in nine days.
On 11 October 2026, HANSOH PHARMA (03692.HK) said it refiled an EU marketing application for almonertinib (Aumseqa®) with the EMA on 29 September, and the EMA confirmed acceptance on 7 October, starting centralised review.
On 8 October 2026, RIBOLIFE (06938.HK) filed a Phase I clinical trial application in the EU for RBD3133, an INHBE-targeting siRNA for obesity.
